The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis

Abstract Background As a potential genetic biomarker, tumor mutation burden (TMB) has made progress in numerous tumors. There are limited data regarding TMB and its prognostic role is controversial in breast cancer. This systematic review and meta-analysis were conducted to assess the prognostic val...

Full description

Bibliographic Details
Published in:	BMC Cancer
Main Authors:	Liyuan Ke, Su Li, Hongxia Cui
Format:	Article
Language:	English
Published:	BMC 2022-11-01
Subjects:	Tumor mutation burden Overall survival Progression-free survival Breast cancer Meta-analysis
Online Access:	https://doi.org/10.1186/s12885-022-10284-1

Similar Items

A Systematic Review and Meta‐Analysis of the Impact of Tumour Mutation Burden on Survival Outcomes in Solid Tumours
by: Aijia Meng, et al.
Published: (2026-05-01)

Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
by: Taobi Huang, et al.
Published: (2021-07-01)

Role of tumor mutational burden in patients with urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis
by: Zhe Wang, et al.
Published: (2025-05-01)

Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer
by: Mengting Zhou, et al.
Published: (2019-11-01)

Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
by: Alexandra Thomas, et al.
Published: (2018-10-01)

Comparison of disease free survival in breast cancer molecular subtypes
by: Maryam Esmati, et al.
Published: (2025-10-01)

Relative efficacy of antibody-drug conjugates and other anti-HER2 treatments on survival in HER2-positive advanced breast cancer: a systematic review and meta-analysis
by: Zian Kang, et al.
Published: (2024-06-01)

Survival of Patients With Primary Cutaneous Melanoma (Stages 0-IIА and IIB-IIC), Depending on the Presence of the <i>BRAF</i> Mutation in the Tumor and Surgical Treatment Option
by: S. A. Yаrgunin, et al.
Published: (2024-03-01)

HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer
by: Yingxue Ren, et al.
Published: (2020-01-01)

Clinicopathologic significance of heat shock protein 60 as a survival predictor in breast carcinoma
by: Qing Wang, et al.
Published: (2024-08-01)

The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients
by: Shengjin Cui, et al.
Published: (2023-02-01)

Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
by: I-Chun Chen, et al.
Published: (2021-10-01)

Survival Analysis of Lung Adenocarcinoma Patients with Exon 19 Del and 21 L858R Mutations Receiving EGFR-TKI Treatment
by: Stephen Johan Prasetyo, et al.
Published: (2023-05-01)

The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients
by: Qing Wu, et al.
Published: (2022-11-01)

Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status
by: Yoshihiko Taniguchi, et al.
Published: (2024-08-01)

Mutations of the PIK3CA gene in patients with breast cancer in the Krasnoyarsk region
by: A. V. Zyuzyukina, et al.
Published: (2024-07-01)

Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study
by: Qianhao Meng, et al.
Published: (2023-02-01)

The effects of dexmedetomidine on postoperative tumor recurrence and patient survival after breast cancer surgery: a feasibility study
by: Jiamei Luo, et al.
Published: (2023-11-01)

Prognostic value of residual cancer burden after neoadjuvant chemotherapy in breast cancer: a comprehensive subtype-specific analysis
by: Soo-Young Lee, et al.
Published: (2025-04-01)

Extended Survival and Prognostic Factors in Endometrial Cancer: A Multivariate Cox Regression Analysis
by: Irene Valencia Téllez, et al.
Published: (2024-12-01)

METASTASIS OF BREAST CANCER IN THE OVARIES. SURVIVAL AND PROGNOSTIC FACTORS
by: S. N. Tadzhibov, et al.
Published: (2017-06-01)

BLM mutation is associated with increased tumor mutation burden and improved survival after immunotherapy across multiple cancers
by: Huiping Shi, et al.
Published: (2024-01-01)

Exploring the effects of doxorubicin on survival rates in glioma patients: a comprehensive systematic review
by: Elyar Mahboubi, et al.
Published: (2025-05-01)

Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database
by: Coralie Courtinard, et al.
Published: (2023-03-01)

Predicting overall survival benefit in previously untreated, unresectable or metastatic melanoma from improvement in progression-free survival: a correlation meta-analysis
by: Peter Mohr, et al.
Published: (2025-06-01)

Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer
by: Masayuki Aboshi, et al.
Published: (2014-02-01)

Predicting the survival probability of functional neuroendocrine tumors treated with peptide receptor radionuclide therapy: Serbian experience
by: Vladimir Vukomanovic, et al.
Published: (2024-01-01)

Diagnostic characteristics, treatment outcomes, and prognostic factors in glucagonomas
by: Eleni Armeni, et al.
Published: (2025-08-01)

Erratum: Predicting the survival probability of functional neuroendocrine tumors treated with peptide receptor radionuclide therapy: Serbian experience
by: Frontiers Production Office
Published: (2024-01-01)

Atezolizumab plus nab-paclitaxel for unresectable, locally advanced or metastatic breast cancer: real-world results from a single academic center in Austria
by: Christine Deutschmann, et al.
Published: (2022-10-01)

Prognostic significance of circulating tumor DNA detection and quantification in cervical cancer: a systematic review and meta-analysis
by: Xiumin Zhao, et al.
Published: (2025-04-01)

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
by: Hisao Imai, et al.
Published: (2015-01-01)

Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non‐squamous non‐small cell lung cancer patients
by: Feiwen Liu, et al.
Published: (2023-06-01)

Evaluation of overall survival and disease-free survival of adjuvant chemotherapy and hormone therapy in patients with breast cancer
by: Kamran Roudini, et al.
Published: (2023-06-01)

Clinical characteristics and prognostic factors of male breast cancer in China
by: Han Lei, et al.
Published: (2024-03-01)

A multivariate retrospective analysis of high‐grade gliomas: Survival and prognostic factors
by: Weiyan Shi, et al.
Published: (2024-08-01)

Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab
by: Che YQ, et al.
Published: (2019-10-01)

Low expression of WWC1, a tumor suppressor gene, is associated with aggressive breast cancer and poor survival outcome
by: Zhanwei Wang, et al.
Published: (2019-07-01)

Clinical and Survival Insights into Carcinoma Penis: A Retrospective Analysis at a Tertiary Care Facility
by: Santosh Kumar Swain, et al.

Histological Aspects and Quantitative Assessment of Ki67 as Prognostic Factors in Breast Cancer Patients: Result from a Single-Center, Cross Sectional Study
by: Irina Niță, et al.
Published: (2020-11-01)